Drug combo shows promise for tough blood cancer

NCT ID NCT02159755

Ongoing Disease control Sponsor: National Cancer Institute (NCI) Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial tests the safety and best dose of combining ibrutinib and palbociclib in 28 patients with mantle cell lymphoma that has come back after treatment. Both drugs block enzymes that help cancer cells grow. The study aims to find a dose that is safe enough to test in larger trials and to see if the combination can shrink tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Ibrutinib and palbociclib (two cancer drugs)
What this could lead to: If this combination proves safe and effective, it could offer a new treatment option for patients with mantle cell lymphoma that has returned after prior therapy.
What could go wrong: This is a very early Phase I trial with only 28 participants, focused on safety and dosing. It is too small to confirm benefit, and side effects from combining two drugs are unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RECURRENT MANTLE CELL LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

mantle cell lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RECURRENT MANTLE CELL LYMPHOMA

Contacts and locations

Locations

NYP/Weill Cornell Medical Center

New York, New York, 10065, United States
Ohio State University Comprehensive Cancer Center

Columbus, Ohio, 43210, United States
UNC Lineberger Comprehensive Cancer Center

Chapel Hill, North Carolina, 27599, United States
Washington University School of Medicine

St Louis, Missouri, 63110, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.